Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “ALK-Positive NSCLC”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Ended earlyNCT02134912
What this trial is testing

S1300: Pemetrexed Disodium With or Without Crizotinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer That Has Progressed After Crizotinib

Who this might be right for
Adenocarcinoma of the LungLarge Cell Lung CancerRecurrent Non-small Cell Lung Cancer+1 more
SWOG Cancer Research Network 1
Early research (Phase 1)Study completedNCT02959619
What this trial is testing

Ensartinib in Non-small Cell Lung Cancer Patients With Positive ALK

Who this might be right for
Solid TumorNon-Small Cell Lung Cancer Metastatic
Betta Pharmaceuticals Co., Ltd. 48
Testing effectiveness (Phase 2)Study completedNCT01752400
What this trial is testing

AUY922 for Advanced ALK-positive NSCLC

Who this might be right for
Non Small Cell Lung Cancer
Massachusetts General Hospital 6
Early research (Phase 1)Active Not RecruitingNCT02321501
What this trial is testing

Ceritinib and Everolimus in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIB-IV Non-small Cell Lung Cancer

Who this might be right for
ALK PositiveLocally Advanced Malignant Solid NeoplasmMetastatic Malignant Solid Neoplasm+3 more
M.D. Anderson Cancer Center 37
Testing effectiveness (Phase 2)UnknownNCT04641754
What this trial is testing

A Study Evaluates the Safety and Efficacy of WX-0593 in ALK -Positive, or ROS1-positive Non-small Cell Lung Cancer

Who this might be right for
Non-small Cell Lung Cancer
Qilu Pharmaceutical Co., Ltd. 176
Post-approval studies (Phase 4)Active Not RecruitingNCT06282874
What this trial is testing

Lorlatinib in Patients With ALK-Positive NSCLC With Brain or Leptomeningeal Metastases

Who this might be right for
Carcinoma, Non-Small-Cell LungBrain MetastasesLeptomeningeal Metastasis
Guangdong Association of Clinical Trials 41
Large-scale testing (Phase 3)Study completedNCT03596866
What this trial is testing

Brigatinib Compared to Alectinib in Adults With Non-Small-Cell Lung Cancer

Who this might be right for
ALK+ Advanced NSCLC
Takeda 248
Testing effectiveness (Phase 2)Study completedNCT03088930
What this trial is testing

Evaluating Crizotinib in the Neoadjuvant Setting in Patients With Non-small Cell Lung Cancer

Who this might be right for
Lung Cancer, Nonsmall Cell
University of Colorado, Denver 3
Not applicableUnknownNCT06410040
What this trial is testing

A Retrospective Study of the Efficacy and Safety of Lolatinib in ALK+ NSCLC Patients With Brain or Meningeal Metastasis

Who this might be right for
ALK-positive Non-small Cell Lung CancerBrain MetastasesMeningeal Metastasis
Sichuan Cancer Hospital and Research Institute 28
Large-scale testing (Phase 3)Study completedNCT01828099
What this trial is testing

LDK378 Versus Chemotherapy in Previously Untreated Patients With ALK Rearranged Non-small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer
Novartis Pharmaceuticals 376
Early research (Phase 1)Active Not RecruitingNCT05441956
What this trial is testing

TGRX-326 Chinese Phase I for Advanced Non-small Cell Lung Cancer (NSCLC)

Who this might be right for
Non-small Cell Lung Cancer
Shenzhen TargetRx Co., Ltd. 198
Not applicableUnknownNCT05991895
What this trial is testing

Real-World Study of Iruplinalkib in the Treatment of ALK-Positive Non-Small Cell Lung Cancer

Who this might be right for
Non-small Cell Lung Cancer (NSCLC)
Jinming Yu 5,000
Not applicableStudy completedNCT02042105
What this trial is testing

A Prospective Epidemiologic Study of ALK-Positive NSCLC in China

Who this might be right for
Non-small-cell Lung Cancer
Guangdong Association of Clinical Trials 3,649
Testing effectiveness (Phase 2)Study completedNCT01562015
What this trial is testing

Ganetespib in Subjects With ALK-Positive Non-Small-Cell Lung Cancer (NSCLC)

Who this might be right for
Non Small Cell Lung Cancer
Synta Pharmaceuticals Corp. 12
Post-approval studies (Phase 4)Not Yet RecruitingNCT07671560
What this trial is testing

Efficacy and Safety of Ensartinib Combined With Anlotinib in Lorlatinib-Resistant ALK-Positive NSCLC

Who this might be right for
ALK-positive, Locally Advanced or Metastatic (TNM Stage IIIB-IV) Non-small Cell Lung Cancer That Has Developed Resistance to Prior Treatment With Lorlatinib
Qiming Wang 80
Large-scale testing (Phase 3)Active Not RecruitingNCT06569420
What this trial is testing

Study Of Comparing SAF-189s With Crizotinib In First Line ALK-Positive Advanced and Metastatic NSCLC

Who this might be right for
Non-Small Cell Lung CancerALK-positiveSAF-189s
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. 275
Not applicableLooking for participantsNCT06862869
What this trial is testing

Real World Clinical Outcomes of Resected ALK-Positive Early Stage NSCLC Patients Treated With Alectinib as Adjuvant Therapy

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Hoffmann-La Roche 800
Testing effectiveness (Phase 2)UnknownNCT05380024
What this trial is testing

Ensartinib as Neoadjuvant Therapy for Patients With ALK Positive Resectable Non-Small Cell Lung Cancer

Who this might be right for
Non Small Cell Lung Cancer
Peking University Cancer Hospital & Institute 10
Testing effectiveness (Phase 2)UnknownNCT04237805
What this trial is testing

A Phase I/II Clinical Study of SAF-189s in Non-small Cell Lung Cancer (NSCLC) Patients

Who this might be right for
Advanced CancerAdvanced Solid TumorLung Cancer, Nonsmall Cell
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. 280
Not applicableUnknownNCT05132218
What this trial is testing

Ensatinib in alK-positive Patients Undergoing Initial Treatment for Advanced Non-small Cell Lung Cancer

Who this might be right for
ALK PositiveNSCLC Stage IIIBNSCLC Stage IV
Peking University Cancer Hospital & Institute 180
Next Page